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Abstract
Background: The FIRST-ABC trial comprises of two pragmatic, multicentre, parallel groups, non-inferiority
randomised clinical trials designed to evaluate the clinical non-inferiority of first-line use of high flow nasal cannula
(HFNC) to continuous positive airway pressure (CPAP) in critically ill children who require non-invasive respiratory
support (NRS).
Objectives: To describe the pre-specified statistical and health economic analysis for the FIRST-ABC trial before
completion of patient recruitment and data collection.
Methods: The statistical analysis plan was designed by the chief investigators and statisticians. We define the primary
and secondary outcomes, summarise methods for data collection and safety monitoring, and present a detailed
description of the planned statistical and health economic analysis.
Results: The primary clinical outcome is time to liberation from respiratory support. The primary effect estimate will be
the adjusted hazard ratio, reported with a 95% confidence interval. As a sensitivity analysis, the primary analysis will be
repeated using time to start weaning of NRS. Subgroup analyses will be performed to test for interactions between the
effect of allocated treatment group and pre-specified baseline covariates. The health economic analysis will follow the
intention-to-treat principle and report the mean (95% confidence interval) incremental costs, quality-adjusted life years
(QALYs) and cost-effectiveness up to 6 months. All analyses will be performed separately for each of the two trials, and
any results will not be combined.
Conclusion: The FIRST-ABC trial will assess the non-inferiority of HFNC compared to CPAP in two parallel trials with
shared infrastructure (step-up RCT and step-down RCT). We have developed a pre-specified statistical and health
economics analysis plan for the FIRST-ABC study before trial completion to minimise analytical bias.
Trial registration: ISRCTN ISRCTN60048867. Registered on 19 June 2019.
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Introduction
Background and rationale
Increasing recognition of the risks of invasive ventilation
for critically ill children, such as ventilator-induced lung
injury and nosocomial infections, has prompted greater
use of non-invasive respiratory support (NRS) tech-
niques in paediatric intensive care units (PICUs) world-
wide [1, 2]. Continuous positive airway pressure (CPAP)
is a mode of NRS which is commonly used and effective,
but can be uncomfortable for some children, and is asso-
ciated with a small but significant risk of complications
such as air-leak and nasal trauma. An alternate mode of
NRS, high-flow nasal cannula (HFNC), has recently
gained popularity since it appears easy to use and well
tolerated by patients [3–6].
The FIRST-ABC Trial is testing the hypothesis that in
critically ill children who require NRS, the first-line use
of high flow nasal cannula (HFNC) is non-inferior to
CPAP in terms of time to liberation from respiratory
support.
This document describes the proposed statistical ana-
lysis plan (SAP) for the trial and has been prepared in
accordance with published guidelines [7].
Objectives
To evaluate the clinical and cost-effectiveness of the use
of HFNC, as compared with CPAP, when used as the
first-line mode of NRS, both as a step-up treatment
(step-up RCT) and as a step-down treatment (step-down
RCT), on the time to liberation from respiratory
support.
Study methods
Trial design and randomisation
FIRST-ABC is a master protocol comprised of two prag-
matic, multicentre, parallel group, non-inferiority rando-
mised clinical trials (step-up RCT and step-down RCT)
with shared infrastructure. Treatment allocation in each
RCT is a 1:1 ratio. Patients are randomised to first-line
use of CPAP or HFNC, with randomisation by permuted
blocks (with variable block length) stratified by site and
age (< 12months versus ≥ 12months).
The trials will be run in up to 25 NHS paediatric crit-
ical care units (PICUs and/or high dependency units,
HDUs) in England, Wales and Scotland.
Sample size
The sample size was calculated as follows: to achieve
90% power with a one-sided type I error rate of 2.5% to
exclude the pre-specified noninferiority margin of HR =
0.75 (corresponding to approximately a 16-h increase in
median time to liberation based on pilot RCT data) re-
quires 508 events to be observed. Based on pilot RCT
data [8], we also anticipate 5% censoring due to death or
transfer, leading to a required sample size of 268 pa-
tients per group in each of the two RCTs. To allow for
withdrawal/refusal of deferred consent, and for exclusion
due to non-adherence in the per protocol (PP) popula-
tion, we will recruit a total sample size of 600 patients in
each of the two RCTs.
Framework
The primary clinical outcomes will be tested for non-
inferiority. Other secondary outcomes will be tested for
superiority, where testing is specified, or analysed using
descriptive statistics only if no testing is specified in this
SAP.
Statistical interim analysis and stopping criteria
The internal pilot phase will be evaluated 6months after
the first site opened to recruitment against pre-specified
progression criteria (number of sites opened, recruit-
ment rate, proportion of patients started on allocated
treatment, changes/escalation to other forms of respira-
tory support and weaning carried out as per protocol).
A single interim analysis will be carried out in each
RCT, after recruitment and follow-up to day 60 of 300
patients. At this point, the following endpoints will be
analysed in the intention to treat (mITT) population
only:
 Time to liberation from respiratory support, which
will be tested using an unadjusted log-rank test, with
early termination of the trial recommended if any
one arm is shown to be superior with p < 0.001
(Peto-Haybittle stopping rule)
 Mortality to day 60, which will be tested using a log-
rank test, with early termination of the trial recom-
mended if any one arm is shown to be superior with
p < 0.05.
For this interim analysis, patients discharged alive
from hospital with no further death after discharge re-
corded are assumed to be alive on the day of data ex-
tract. Patients who have withdrawn or refused consent
for access to medical records will be censored on the
date of withdrawal or refusal of consent.
Timing of final analysis
The final analysis for each RCT will be performed no
earlier than 6 months after the last patient has been ran-
domised to that RCT.
Timing of outcome assessments
Following randomisation, details of respiratory support
are recorded hourly for the first 6 h, and six hourly
thereafter until the end of respiratory support (or to at
least 48 h following randomisation, if patients are
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transferred to another unit or ward in a different hos-
pital). At the relevant timepoints, physiological parame-
ters (e.g. fraction of inspired oxygen (Fi02) Oxygen
saturation (Sp02)) and sedation use are recorded if pa-
tients are on either HFNC or CPAP. Patient comfort is
assessed at least six hourly while patients are on HFNC
or CPAP.
Survival status is recorded at unit discharge, at ultim-
ate discharge from critical care (if the patient has been
transferred to another critical care unit), at discharge
from acute hospital and at days 60 and 180 post-
randomisation.
Parental stress is measured using the Parental Stressor
Scale: PICU [9] at/around the time of consent (antici-
pated to be within 24–48 h of randomisation). Quality of
life (measured using age-appropriate Pediatric Quality of
Life Inventory (Peds-QL) [10] and The Child Health
Utility 9D (CHU-9D) [11]) and health services/resource
use is assessed at 6 months post-randomisation.
Statistical principles
Confidence intervals and p values
The primary clinical outcome will be tested for non-
inferiority. Other secondary outcomes will be tested for
superiority, where testing is specified, or analysed using
descriptive statistics. Statistical tests will be two-sided
with significance set at P < 0.05 unless otherwise speci-
fied. Effect estimates will be reported with 95% confi-
dence intervals. There will be no adjustment for
multiple testing. The results of subgroup analyses will be
interpreted taking into account accepted criteria for
credible subgroup effects [12, 13]. All analyses described
in this SAP will be performed separately for each of the
two RCTs, and any results will not be combined.
Adherence and protocol deviations
Exposure
Exposure to the intervention will be assessed by the fol-
lowing parameters, which will be calculated for each
treatment group and summarised using descriptive sta-
tistics (mean, standard deviation, median and interquar-
tile range (IQR), or counts and percentages for binary
and categorical variables) unless otherwise specified:
 In patients randomised to CPAP, pressure (in cm
H2O as a continuous variable, and grouped as < 7
cm, 7–8 cm, > 8 cm), by hour during the first 6 h
from randomisation
 In patients randomised to HNFC, flow rate (as % of
recommended starting rate, and group ed. as ≤ 50%,
51–75%, 76–85%, 86–95%, ≥ 95% of recommended
starting rate), by hour during the first 6 h from
randomisation
 Time from first recorded observation meeting
weaning/failure/stopping criteria to time of weaning/
switch or escalation/treatment stop
Further treatment patterns across each group and time
from first meeting weaning criteria to start of weaning
attempt will be explored using summary statistics and
graphic methods only; no formal statistical testing will
be performed.
Protocol adherence
The number and % of patients will be reported for each
of the following potential protocol deviations: did not
start randomised treatment (with details provided on
what respiratory support, if any, was started), switched
or escalated respiratory support without meeting treat-
ment failure criteria; weaning attempt made without
meeting weaning criteria, respiratory support is discon-
tinued while FiO2 ≥ 0.3 and moderate or severe respira-
tory distress is documented.
Analysis population
All randomised patients will be included in the
intention-to-treat (ITT) population. A modified ITT
(mITT) population will be used for analysis of the pri-
mary endpoint, consisting of the ITT populations ex-
cluding those with no recorded respiratory support post-
randomisation. The per protocol (PP) population will
consist of all randomised patients who met the eligibility
criteria and were started on the randomised respiratory
support, as the first respiratory support post-
randomisation.
Trial population
Screening data
The following summaries of screening will be presented
for each trial:
 Number and % of patients screened who did not
meet inclusion criteria, overall and by criteria
 Of the patients who met the inclusion criteria,
number and % who met exclusion criteria, overall
and by criteria
 Of the eligible patients (i.e. met inclusion criteria
and did not meet exclusion criteria), number and %
not randomised, overall and by reason (if known)
Eligibility
Inclusion criteria
1) Admitted/accepted for admission to PICU/HDU
2) Age > 36 weeks corrected gestational age and < 16
years
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3) Assessed by the treating clinician to require NRS,
EITHER
A. For an acute illness (step-up RCT) OR
B. Within 72 h of extubation following a period of
invasive ventilation (step-down RCT)
Exclusion criteria
1) Assessed by the treating clinician to require
immediate intubation and invasive ventilation due
to severe hypoxia, acidosis and/or respiratory
distress, upper airway obstruction, inability to
manage airway secretions or recurrent apnoeas
2) Tracheostomy in place
3) Received HFNC/CPAP for > 2 h in the prior 24 h
4) On home non-invasive ventilation prior to PICU/
HDU admission
5) Presence of untreated air-leak (pneumothorax/
pneumomediastinum)
6) Midfacial/craniofacial anomalies (unrepaired cleft
palate, choanal atresia) or recent craniofacial
surgery
7) Agreed ‘not for intubation’ or other limitation of
critical care treatment plan in place
8) Previously recruited to the FIRST-ABC trial*
9) Clinician decision to start other form of NRS (i.e.
not HFNC or CPAP)
*i.e. patients randomised to the step-up RCT will not
be eligible for randomisation to the step-down RCT.
Similarly, patients once enrolled to the step-up or step-
down RCTs and satisfied the primary outcome of being
liberated from respiratory support will not be eligible for
re-randomisation to the trial even if they require further
episode(s) of NRS during the same or on subsequent
hospital admissions.
Full details of the study population including eligibility,
randomisation and treatment delivery can be found in
the FIRST-ABC trial protocol [14].
Recruitment
CONSORT [15] flow diagrams for the ITT and PP pop-
ulations will be completed for each trial. These will in-
clude number and percentage of patients starting
respiratory support post-randomisation, and numbers
and percentage of patients by availability of primary
endpoints.
Consent and withdrawal
The parent/legal guardian of trial participants will be
asked to consent to one or more aspects of the trial
(continued participation/treatment; ongoing data collec-
tion; completion of the Parental Stressor Scale: PICU, to
receive a follow-up questionnaire at 6 months post-
randomisation; sharing of anonymised data) as soon ap-
propriate and practical after randomisation (usually
within 24–48 h of randomisation). Once given, consent
can be withdrawn at any time up to the end of the study.
Data collected up to the point of refusal or withdrawal
of consent to data collection will be retained, unless par-
ents specifically request otherwise.
If a patient is transferred to another hospital while still
on trial treatment, all efforts will be made to continue to
collect a minimum trial dataset (including the primary
outcome measure).
Baseline patient characteristics
Baseline data is collected at critical care admission via
data linkage to Paediatric Intensive Care Audit Network
(PICANet), and directly via trial CRF for physiology at
randomisation. The following baseline demographic and
clinical data will be summarised in the mITT and PP
populations, by allocated treatment group (using mean,
standard deviation, median and interquartile range
(IQR), or counts and percentages for binary and categor-
ical variables), but not subjected to statistical testing:
In both trials: age (continuous in years, and by age
group ≤ 28 days, 29–180 days, 181–364 days, 1–4 years,
5–10 years, 11–15 years), sex; respiratory distress (mild,
moderate or severe), heart rate (bpm and in age-
corrected centiles), SpO2, FiO2, SpO2/FiO2 ratio,
COMFORT-B score [16] (where available), presence of
pre-specified comorbidities, reason for admission (step-
up RCT) or reason for invasive ventilation (step-down
RCT).
In the step-up trial only: respiratory support received
in 24 h prior to randomisation (type and duration),
whether on respiratory support at time of randomisa-
tion, general anaesthesia for surgery/procedure in the
6 h preceding randomisation.
In the step-down trial only: duration of invasive venti-
lation (continuous in hours, and by duration < 5 days vs.
≥ 5 days).
Analysis
Outcome definitions
Primary outcome
 The primary clinical outcome is time to liberation
from respiratory support, defined as the time from
randomisation to the start of a 48-h period during
which the child was free of all forms of respiratory
support.
Secondary outcomes
 Mortality at PICU/HDU discharge, day 60 and day
180. Mortality at discharge from the PICU/HDU
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will be defined as death due to any cause before
discharge to any location providing a level of care
less than level 2 (high dependency care). Mortality
at day 60 and 180 will be calculated as binary
endpoints using all patients with known survival
status at those times, and additionally using time to
event methods with surviving patients censored at
date last known to be alive (to a maximum of day
180).
 Rate of (re) intubation at 48 h. Intubation at 48 h is
defined as present if the child has started any
invasive ventilation at any time up to and including
48 h and zero minutes after time of randomisation.
Patients are included in the denominator if they
have received invasive ventilation by 48 h, or are
known not to have received any invasive ventilation
from randomisation to 48 h following
randomisation. Patients discharged from PICU/HDU
before 48 h are assumed not to have been invasively
ventilated post discharge.
 Duration of PICU/HDU and acute hospital stay.
Duration of PICU/HDU will be calculated as the
sum of the duration (in days and fractions of days)
from the date and time of randomisation to the date
and time of first discharge from a critical care unit
(or ultimate discharge from critical care if
transferred directly to another critical care unit) or
to death in the critical care unit. Duration of acute
hospital stay will be calculated as the duration in
days from the date of randomisation to the date of
ultimate acute hospital discharge or death in acute
hospital.
 Patient comfort, during randomised treatment and
during NRS (i.e. HFNC and/or CPAP), measured
using the COMFORT-B score. Patient comfort is
measured during HFNC or CPAP using the
COMFORT-B score which will be summarised at
patient level using the median of all recorded scores.
To be measured in all patients with at least one re-
corded COMFORT-B score in the first 6 h of sup-
port following randomisation, AND, while
respiratory support continues, at least one
COMFORT-B score per day during at least the first
48 h of respiratory support.
 Proportion of patients in whom sedation is used
during NRS. Need for sedation will be defined as the
proportion of patients in whom sedation is used
NRS at any point until liberation from respiratory
support. Patients will be included in the
denominator if they have a minimum of three non-
missing observations in the first 6 h of respiratory
support, AND, while respiratory support continues,
at least two non-missing observations per day during
the first 48 h of respiratory support.
 Parental stress, in hospital at/around the time of
consent, measured using the Parental Stressor Scale:
PICU. Parental stress will be measured using the
validated Parental Stressor Scale: PICU (PSS: PICU)
in hospital at/around the time of consent
(anticipated to be within 24–48 h post-
randomisation). This consists of 37 items each
scored in whole numbers from 1 (not stressful) to 5
(extremely stressful). A total score is calculated as
the mean of all completed items [9].
 Health-related quality of life at 6 months. Health-
related quality of life at 6 months will be measured
using the age-appropriate Paediatric Quality of Life
Inventory (Peds-QL)32 and the Child Health Utility
9D (CHU-9D) completed by parents at 6 months
post-randomisation. The PEDS-QL instrument uses
a different set of question of each age group of 1–12
months, 13–24 months, 2–4 years, 5–7 years, 8–12
years and 13+ years. For each age group, an overall
score is calculated on a scale of 0–100 with higher
scores indicating better quality of life. In infants
under 2 years, five subscales are defined, relating to
physical functioning, physical symptoms, emotional
functioning, social functioning and cognitive func-
tioning, and in children of 2 years and over, four
subscales are defined, relating to physical function-
ing, emotional functioning, social functioning and
school functioning [10]. CHU-9D was developed
with children aged 7–17 and is designed to produce
utility values for use in calculating quality-adjusted
life years (QALYs) [11].
 Total costs at 6 months. Cost will be calculated from
patient-level resource use data on resources required
to deliver the intervention, length of stay in PICU/
HDU and acute hospital, for the index admission
and any readmissions before 6 months, and use of
personal health services after acute hospital dis-
charge within 6 months post-randomisation.
Patient-level resource use data will be valued using
appropriate unit costs data from the NHS Payment
by Results database, unit costs of health and social
care (PSSRU) and from local Trust Finance Depart-
ments, to calculate total costs at 6 months.
 Quality-Adjusted Life Years (QALYs) at 6 months.
The health outcome for the economic evaluation
will be summarised using QALYs, which unites
quantity (survival) and quality of life into a single
metric. To do this, HRQoL, which is measured on
an index scale of 1 (equals full health) and 0 (equals
death), at 6 months will be assessed using the CHU-
9D instrument, with valuation using the validated
UK tariffs [11]. HrQoL data will be combined with
the survival data to calculate QALYs at 6 months.
QALYs will be calculated by valuing each patient’s
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survival time by their HrQoL at 6 months according
to the “area under the curve” approach. For 6-
month survivors, QALYs will be calculated using the
CHU-9D scores at 6 months, assuming an CHU-9D
score of zero at randomisation, and a linear
interpolation between randomisation and 6 months.
For decedents between randomisation and 6 months,
we will assume zero QALYs.
 Incremental net monetary benefit gained at a
willingness-to-pay of £20,000 per QALY at 6 months
associated with HFNC vs. CPAP. Net monetary
benefits will be calculated by valuing QALY gains at
the NICE recommended (£20,000) willingness to pay
(WTP) for a QALY gain and subtracting
incremental costs.
Clinical effectiveness analysis methods
Primary outcome
The median (IQR) time to liberation from respiratory
support will be reported for each arm using Kaplan-
Meier estimates and compared between groups using
Cox regression, unadjusted and adjusted for important
baseline characteristics (including shared frailty at the
site level). The covariates for inclusion in the regression
models are the following, which have been selected a
priori based on an established relationship with outcome
for critically ill children:
In both RCTs:
 Age (< 12 months versus ≥ 12 months)
 Severity of respiratory distress at randomisation
(severe versus mild/moderate)
 SpO2:FiO2 ratio at randomisation (linear)
 Co-morbidities (none versus neurological/
neuromuscular versus other)
Step-up RCT only:
 Reason for admission (bronchiolitis versus other
respiratory (airway problem, asthma/wheeze or any
other respiratory) versus cardiac versus other
(neurological, sepsis/infection, any other)
 Whether the patient was on NRS at randomisation
(yes/no)
Step-down RCT only:
 Length of prior invasive mechanical ventilation
(IMV) (< 5 days versus ≥ 5 days)
 Reason for IMV (cardiac versus other)
The primary effect estimate will be the adjusted hazard
ratio, reported with a 95% confidence interval. HFNC
will be considered non-inferior to CPAP if the lower
bound of the 95% confidence interval is above 0.75 in
both the mITT and PP populations. Patients without a
recorded time of liberation will be censored at date and
time of death (for patients who died while on treatment)
or at date and time of last recorded respiratory support.
The assumption of proportional hazards will be explored
by fitting a Cox model with time-dependent covariates.
Exploratory analyses will test for an interaction be-
tween the subgroup categories defined below (or sub-
group variable for linear interactions) and the treatment
group in a multilevel Cox regression model, adjusted for
the same baseline variables as the primary analysis. For
linear interactions, the interaction effect will be illus-
trated by calculating the adjusted hazard ratio within five
categories at quintiles of the continuous variable. Each
subgroup will be considered separately:
In both RCTs:
 Age
 Severity of respiratory distress at randomisation
 SF ratio at randomisation (interaction test as a linear
covariate, with effect illustrated by calculating the
adjusted hazard ratio within five categories at
quintiles of the continuous variable)
 Co-morbidities
Step-up RCT only:
 Reason for admission
 Whether the patient was on NRS at randomisation
Step-down RCT only:
 Length of prior IMV
 Reason for respiratory support post-extubation, cate-
gorised as planned (randomisation followed by extu-
bation), indeterminate (extubation followed by
randomisation within 60 min of extubation) vs res-
cue (extubation followed by randomisation more
than 60 min post extubation) breathing support
 Reason for IMV
We will treat age as a continuous variable and deter-
mine whether the model goodness-of-fit is better versus
treating age as a categorical term for any analyses focusing
on those over the age of 12months. We anticipate a high
proportion of patients will be aged < 12months, and
therefore, exploration of age effects in the older ages will
only be conducted if there are sufficient patient numbers.
As a sensitivity analysis, the primary analysis will be
repeated using time to start weaning of NRS (i.e. dur-
ation of ‘acute’ respiratory support), time to meeting ob-
jective ‘readiness to wean NRS’ criteria and time from
start of support to liberation from support.
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Secondary outcomes
Binary outcomes (mortality at discharge from critical
care, at 60 and 180 days post-randomisation, (re) intub-
ation at 48 h, sedation use during randomised treatment,
sedation use during HFNC or CPAP) will be reported in
each treatment group, in the PP and mITT populations.
Absolute risk reduction and unadjusted odds ratios will
be reported with 95% confidence intervals. Multilevel lo-
gistic regression (adjusted for the same baseline variables
as the adjusted analysis of the primary outcome) will be
used to calculate adjusted odds ratios with 95% confi-
dence intervals.
Continuous outcomes (duration of PICU/HDU and
hospital stays) will be summarised by treatment groups,
stratified by survival status, in the PP and mITT popula-
tions. Mean difference between groups will be calcu-
lated, with 95% confidence interval using bootstrapping
to account for anticipated non-normality in the
distribution.
Duration of survival to day 180 will be plotted as
Kaplan-Meier survival curves, in the PP and mITT pop-
ulations, and unadjusted and adjusted hazard ratios with
95% confidence intervals will be calculated using Cox re-
gression models.
Parent-reported outcomes (PSS: PICU score, PEDS-
QL score, CHU-9D score) will be summarised by treat-
ment groups, in the PP and mITT populations. Mean
difference between groups will be calculated, with 95%
confidence interval using bootstrapping to account for
anticipated non-normality in the distribution. Linear re-
gression will be used to calculate adjusted mean
differences.
For each patient, their median Comfort-B score while
on randomised treatment and their median COMFORT-
B score while on either HFNC or CPAP will be calcu-
lated. These median scores will be summarised by treat-
ment groups, using median (IQR) and mean (sd). The
number and % of patients with any recorded
COMFORT-B score ≥ 23 while on randomised treat-
ment and the number and % of patients with any re-
corded COMFORT-B score ≥ 23 while on either HFNC
or CPAP will be reported. Mean difference between
groups will be calculated, with 95% confidence interval
using bootstrapping to account for anticipated non-
normality in the distribution. Linear regression will be
used to calculate adjusted mean differences.
Cost-effectiveness analysis methods
A full cost-effectiveness analysis (CEA) will be under-
taken to assess the relative cost-effectiveness of HFNC
versus CPAP according to the intention-to-treat
principle. Resource use and outcome data collected as a
part of the trial will be used to report cost-effectiveness
at 6 months by randomised treatment group.
Following recent National Institute for Health and
Care Excellence (NICE) recommendations, the cost-
effectiveness analysis will take a health and personal
health services perspective. The primary sources of the
resource use data will be the FIRST-ABC trial case re-
port forms (CRFs), PICANET data, hospital episode sta-
tistics (HES) database and individual health service
questionnaires (HSQ) on the use of personal health ser-
vices which are posted to surviving patients at 6 months
following randomisation. Resource use data from the
PICU/HDU stay will be taken from the CRF and linked
to routine data from PICANet. Data on the level of care
for PICU/HDU bed-days will be gathered through rou-
tine collection of the Paediatric Critical Care Minimum
Dataset (PCCMDS) in the participating centres via the
PICANet database. Information on subsequent PICU/
HDU and hospital admissions will be obtained via data
linkage with PICANet and HES database. Use of primary
care and community health services will be assessed by
HSQ at 6 months. Resource use data from the trial data-
sets, PICANet data, HES database and 6months’ follow-
up questionnaires will be combined with unit costs from
the NHS Payment by Results database, unit costs of
health and social care (PSSRU) and from local Trust Fi-
nance Departments, to report the total costs per patient
at 6 months for both randomised groups.
Missing data in costs and HrQoL will be handled with
multiple imputation, assuming the data are missing at
random (MAR) conditional on the observed data (see
below for details on methods used to handle missing
data). On the imputed datasets, the cost-effectiveness
analysis will use a Bivariate Seemingly Unrelated Regres-
sion model to allow for correlation between costs and
QALYs and multilevel structure of the data. We will cal-
culate the interclass correlation coefficient (ICC) which
measures the proportion of the overall variation that oc-
curs at the cluster level [17]. If ICC > 10%, we will use
multilevel models (MLM) to handle clustering and avoid
potential biases and incorrect inferences. The incremen-
tal results from multiply-imputed datasets will sum-
marised using Rubin’s rule [18].
The CEA will follow the intention-to-treat principle
and report the mean (95% confidence interval) incre-
mental costs, QALYs and net monetary benefit at 6
months. The base case analysis will report the incremen-
tal effects of randomisation to a HFNC strategy versus
CPAP. We will also report the probability that the inter-
vention compared to usual care is cost-effective at differ-
ent levels of WTP for a QALY gain.
Sensitivity analysis for cost-effectiveness
The following sensitivity analyses will be performed to
check the robustness of primary CEA results at 6
months.
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a. HRQoL data: A mapping technique will be used to
predict the CHU-9D scores from the PedsQL re-
sponses [19]. We will also explore alternative distri-
butional assumptions for QALYs.
b. Cost data: Because of the likely skewed distribution
of costs, we will consider several distributions that
can give a better fit of cost data. We will assess the
implications of potential double-counting of in-
patient costs (e.g. costs for vasopressors) across the
three sources of resource data.
Handling of missing data
As the primary endpoint will be analysed using time-to-
event methods, patients with missing data will be in-
cluded in the analysis as censored at the point of last re-
corded NRS. Time to censoring will be compared
between arms using Kaplan-Meier curves to explore the
assumption of censoring at random, and if necessary, a
competing risk approach may be taken with death and/
or withdrawal of consent while on treatment considered
as a competing risk.
Multiple imputation will be used to complete missing
data in secondary outcomes, costs and HRQoL, under
the assumption that the responses are missing at ran-
dom (MAR) conditional on the observed data. Multiple
imputation will be undertaken using the Multivariate
Imputation using Chained Equations algorithm, with the
model including all baseline variables included in the ad-
justed models and all outcome variables. The number of
imputations will be determined according to level of
missingness in the outcome variables. Models will be fit-
ted in each imputed dataset and results combined using
Rubin’s rules.
Additional analyses
The primary analysis will be repeated adjusting for
adherence to allocated intervention using a structural
mean model with an instrumental variable of allo-
cated treatment to estimate the complier average
causal effect of treatment. Adherence will be mea-
sured for each patient as the proportion of all events
(weaning, escalation, switch or withdrawal of support)
which were classified as non-adherent, where for each
observation non-adherence is as previously de-
fined under the section headed 'Protocol adherence'.
Children who did not start on the randomised treat-
ment will be recorded as having 100% non-adherence.
A descriptive analysis of baseline characteristics and
some secondary outcomes (mortality and length of
stay outcomes, where available) will be performed for
patients who did not start any respiratory support
post randomisation (i.e. those excluded from the
mITT analysis).
Safety
Specified adverse events (nasal trauma, facial/neck
trauma, abdominal distension, pneumothorax, pneumo-
mediastinum, subcutaneous emphysema, facial thermal
injury, respiratory arrest, cardiac arrest), and any other
possibly related adverse event, are recorded from ran-
domisation up to 48 h after date/time of liberation of re-
spiratory support.
The percentage of patients experiencing one or more
adverse event in patients who commenced respiratory
support post randomisation will be compared between
groups using Fisher’s exact test. Counts and percentages
of adverse events, and serious adverse events, overall and
by type, will be presented by allocated treatment group.
Statistical software
All analyses will be conducted in Stata/SE Version 16.1
64-bit x86-64 (StatCorp LLC, College Station, TX).
Some additional cost-effectiveness analysis may be car-
ried out in R if required.
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